Drug Discovery And Targeted Drug Delivery Systems:A Review Of Current Approaches, Nanotechnology And Translational Challenges

Dr. Rekha Kumari Gupta[1], Dr. Parul Gupta[2]

[1] *2nd year MD scholar, Department of Rasa Shastra & Bhaishajya Kalpana GACH PATNA*
Email: *rekhagupta4512@gmail.com*

[2]*Assistant Professor, Department of Rasa Shastra & Bhaishajya Kalpana GACH PATNA*

****CORRESPONDING AUTHOR***
Dr. Rekha Kumari Gupta
2nd year MD scholar Department of Rasa Shastra & Bhaishajya Kalpana GACH PATNA
Email: *rekhagupta4512@gmail.com*

ABSTRACT

Drug discovery is a multidisciplinary process that transforms a biological hypothesis or chemical lead into a candidate suitable for clinical development. It integrates target identification, lead discovery, optimization, preclinical assessment, clinical investigation, regulatory review and post-marketing surveillance. A parallel challenge is to deliver an active pharmaceutical ingredient at an appropriate concentration and time to the intended biological site while limiting exposure of non-target tissues. Targeted drug delivery systems have therefore become an important area of pharmaceutical research. Passive targeting exploits differences in tissue physiology and carrier disposition, whereas active targeting uses ligands that recognize receptors or other molecular features on target cells. Nanotechnology has expanded these approaches through liposomes, polymeric nanoparticles, lipid nanoparticles, micelles, dendrimers and hybrid carriers. This review summarizes the major stages of drug discovery, methodological approaches to targeted delivery, important nanocarrier platforms, passive and active targeting, formulation considerations, therapeutic opportunities and barriers to clinical translation. Particular attention is given to the limitations of relying on enhanced permeability and retention alone and to the importance of physicochemical characterization, reproducible manufacturing, safety assessment and clinically relevant models. The review also discusses the potential relevance of contemporary drug-delivery science to pharmaceutical research in Rasa Shastra and Bhaishajya Kalpana, while emphasizing that modern nanomedicine concepts should be connected with Ayurvedic formulations only through appropriate experimental evidence.

Keywords: Drug discovery; targeted drug delivery; nanoparticles; nanomedicine; passive targeting; active targeting; liposomes; pharmaceutical development; Rasa Shastra; Bhaishajya Kalpana.

How to cite this article: Dr. Rekha Kumari Gupta, Dr. Parul Gupta, Drug Discovery And Targeted Drug Delivery Systems:A Review Of Current Approaches, Nanotechnology And Translational Challenges. Int J Drug Deliv Technol. 2026;16(87s): 1430-1435; DOI: 10.25258/ijddt.16.87s.150

I. INTRODUCTION

Drug discovery and development represent a long, sequential and multidisciplinary pathway through which potential therapeutic agents are identified, optimized and evaluated for human use. Regulatory descriptions of the modern pathway generally include discovery and development, preclinical research, clinical research, regulatory review and post-market safety monitoring [1]. The scientific process incorporates medicinal chemistry, molecular biology, pharmacology, toxicology, pharmaceutics, bioanalysis and clinical research. The objective is not simply to identify a biologically active compound, but to establish an acceptable balance among efficacy, safety, pharmacokinetics, formulation characteristics and clinical usefulness.

Even when a drug has appropriate intrinsic pharmacological activity, its therapeutic performance can be limited by poor solubility, instability, rapid metabolism, inadequate tissue penetration, non-specific distribution or dose-limiting toxicity. Drug-delivery systems seek to modify these limitations by controlling the route, rate, duration and location of drug exposure. Targeted delivery extends this concept by attempting to

increase the proportion of drug reaching a desired tissue or cell population while reducing exposure elsewhere [2,3].

Nanomedicine has provided a particularly active platform for targeted delivery. Nanoparticle systems can be engineered by controlling parameters such as size, surface chemistry, composition, morphology and drugloading characteristics. These parameters influence circulation, biodistribution, cellular interactions, clearance and release behaviour [4]. Liposomes, for example, have progressed from experimental vesicular systems to clinically established drug-delivery platforms [5].

However, targeted delivery should not be equated with guaranteed selective therapy. Biological heterogeneity, variable receptor expression, immune clearance, tissue barriers, differences between animal models and humans, and manufacturing complexity can substantially affect performance [6,7].




Figure 1. Drug discovery and development pathway.

2. MATERIALS AND METHODS

This manuscript was prepared as a narrative review using a structured literature-identification approach. Literature was searched using PubMed-indexed records, peer-reviewed journal articles and authoritative regulatory information. Search concepts included combinations of the terms “drug discovery”, “drug development”, “targeted drug delivery”, “nanoparticle drug delivery”, “active targeting”, “passive targeting”, “nanomedicine”, “liposomes”, “clinical translation” and “drug delivery systems”.

Priority was given to peer-reviewed review articles and primary literature with clear relevance to drugdiscovery pathways, targeted delivery, nanocarrier design and clinical translation. The U.S. Food and Drug Administration drug-development pathway was used for the general description of discovery, preclinical research, clinical research, regulatory review and post-market monitoring [1]. Bibliographic details of the principal scientific references were cross-checked against PubMed and/or journal records where available. Articles were synthesized thematically rather than statistically because the objective was a broad pharmaceutical review and not a quantitative systematic review or meta-analysis.

The review included literature addressing: (i) stages of drug discovery and development; (ii) principles of targeted delivery; (iii) passive and active targeting; (iv) nanoparticle and liposomal platforms; (v) biological barriers and nano–bio interactions; (vi) manufacturing, characterization and translational challenges; and (vii)

potential interdisciplinary relevance to pharmaceutical research.

3. RESULTS AND DISCUSSION

3.1 Drug Discovery and Development Pathway

The modern drug-development pathway can be considered as a continuum beginning with identification of a disease mechanism or therapeutic hypothesis and progressing through candidate selection, preclinical evaluation, clinical investigation and regulatory assessment [1]. Discovery research may originate from natural products, synthetic chemistry, biological molecules, repurposing strategies, phenotypic screening, target-based screening or computational approaches.

Preclinical development provides information needed to support first-in-human studies, including pharmacology and toxicology. Clinical development then evaluates safety, dose, pharmacokinetics and therapeutic effects in human participants. Regulatory review examines the totality of submitted evidence before marketing authorization, followed by continued safety monitoring after a product enters wider clinical use [1,8].

3.2 From Lead Identification to Lead Optimization

Lead identification aims to find molecules or biological entities with reproducible activity against a relevant target or disease phenotype. High-throughput screening, structure-based approaches, computational modelling, fragment-based discovery and natural-product research can all contribute to this stage. A lead is not necessarily a drug candidate; it must undergo optimization to improve potency, selectivity, physicochemical characteristics, metabolic stability and safety.

Drug-like properties are closely connected to delivery. A compound with strong biological activity may still be

unsuitable for conventional administration because of low aqueous solubility, poor absorption, rapid degradation or extensive off-target distribution. Consequently, formulation and delivery considerations may need to be incorporated early rather than treated as a separate final step.

3.3 Targeted Drug Delivery: Basic Concept

Targeted drug delivery aims to alter drug distribution so that therapeutic exposure is preferentially increased at a desired site or reduced at selected non-target sites. Targeting can be achieved through carrier properties, physiological mechanisms, ligand–receptor interactions, externally applied physical stimuli or combinations of these approaches [2,3].

Nanocarrier-based delivery is attractive because the carrier can be designed to carry a drug payload and can be modified independently of the pharmacologically active molecule. This separation of carrier function from drug function allows researchers to adjust circulation behaviour, surface characteristics and release kinetics [4].

Figure 2. Conceptual framework of targeted drug delivery




Figure 2. Conceptual framework of targeted drug delivery: passive and active approaches.

3.4 Passive Targeting

Passive targeting describes preferential delivery resulting from the physicochemical properties of the carrier and the biological characteristics of the target tissue, rather than from a specific ligand–receptor recognition event. In oncology, the enhanced permeability and retention (EPR) effect has historically been an important conceptual basis for passive nanoparticle accumulation in some solid tumours [3,9].

The EPR phenomenon is not uniform. Tumour vascular permeability, interstitial pressure, stromal architecture, blood flow and immune interactions vary between tumour types and between patients. Consequently, EPRmediated accumulation observed in experimental models may not translate directly to humans [9,10].

3.5 Active Targeting

Active targeting involves decorating a drug carrier with a ligand capable of recognizing a molecular feature associated with the target cell or tissue. Investigated ligand classes include antibodies, antibody fragments, peptides, aptamers, proteins, polysaccharides and small molecules [11].

Active targeting therefore adds a biological recognition step to carrier design. However, ligand binding does not eliminate the need for appropriate biodistribution, tissue penetration and drug release. Target expression can be heterogeneous, receptor accessibility may be limited, and the carrier may be removed by the mononuclear phagocyte system before reaching the intended cells [4,11].

Figure 4. Active targeting: simplified ligand–receptor interaction




Figure 4. Simplified ligand–receptor recognition in active targeted delivery.

3.6 Major Nanocarrier Platforms

Several carrier platforms have been investigated for targeted and controlled delivery. Liposomes consist of lipid bilayer vesicles capable of carrying hydrophilic compounds in an aqueous compartment and incorporating hydrophobic compounds within the lipid phase. Their development has included PEGylation, remote loading, triggered release and ligand-mediated targeting [5]. Polymeric nanoparticles and micelles offer additional flexibility in polymer composition, drug loading and degradation. Lipid nanoparticles provide a versatile platform for delivery of nucleic acids and other payloads. Dendrimers possess highly branched architectures that can be functionalized with drugs or targeting groups. Hybrid systems attempt to combine useful properties from multiple carrier classes [4,12].

Figure 3. Representative nanocarrier platforms




Figure 3. Representative nanocarrier platforms used in drug delivery.

3.7 Physicochemical Characteristics and Biological Fate

Nanoparticle size, size distribution, surface charge, morphology, composition, hydrophobicity and drugloading characteristics can influence biological fate. These variables affect protein adsorption, cellular uptake, circulation, organ distribution and clearance [4,6]. Therefore, a targeted formulation should be treated as a defined pharmaceutical product with critical quality attributes rather than simply as a nanoscale object. For translational development, characterization must be reproducible and linked to biological performance. Parameters such as particle size and distribution, morphology, surface properties, encapsulation efficiency and drug-release behaviour can become important quality attributes. Variations introduced during scale-up may alter the in vivo behaviour of a formulation, making process control and batch-to-batch consistency essential [6,7].

Figure 5. Major factors influencing nanoparticle biological fate




Figure 5. Major formulation and biological factors influencing nanoparticle fate.

3.8 Clinical Translation and Safety Challenges

The transition from laboratory studies to clinical use remains one of the major challenges in nanomedicine. A formulation may demonstrate favourable activity in cell culture or animal models but show a different distribution pattern or therapeutic response in humans. This can arise from differences in vascular architecture, immune clearance, tumour heterogeneity, extracellular matrix, pharmacokinetics and drug release [6,9].

Manufacturing is another critical component. Nanomedicines require control over formulation composition and physicochemical properties, and changes in manufacturing conditions can influence product performance. Reviews of clinical translation highlight the importance of critical quality attributes,

analytical methods, scaleup, batch consistency, suitable preclinical models and early consideration of regulatory requirements [6,7].

Safety assessment should consider both the active drug and the carrier. Potential concerns include immunological reactions, organ accumulation, altered clearance, degradation products and long-term exposure. A favourable delivery profile in one disease cannot be assumed to apply to another.

3.9 Targeted Delivery Beyond Cancer

Although cancer has been a major focus of targeted nanomedicine, targeted and controlled delivery strategies have also been investigated for inflammatory disorders, infectious diseases, neurological conditions, gene therapy and other therapeutic areas [4,12]. The biological requirements differ substantially among indications.

3.10 Relevance to Rasa Shastra and Bhaishajya Kalpana

Rasa Shastra and Bhaishajya Kalpana are concerned with pharmaceutical processing, formulation and administration of Ayurvedic medicines. Contemporary analytical and drug-delivery technologies may provide tools for characterizing formulation properties, stability, dissolution, release and biological interactions. However, modern terms such as “nanoparticle”, “targeted delivery” or “nano-drug” should not be assigned to an Ayurvedic formulation solely because a preparation contains fine particles or because a conceptual similarity is proposed. Demonstrating a targeted-delivery mechanism requires appropriate particle characterization, biological distribution studies, mechanistic evidence and safety assessment.

3.11 Future Perspectives

Future targeted-delivery research is likely to emphasize precision formulation, better understanding of nano– bio interactions, patient and disease heterogeneity, stimuli-responsive release, combination delivery and computational optimization. Integration of molecular profiling with formulation design may improve the selection of patients and biological targets.

A clinically useful targeted delivery system should ultimately demonstrate a measurable benefit relevant to patients. Improved localization alone is insufficient if it does not translate into better efficacy, safety, dosing convenience or another meaningful clinical outcome [4,6,9].




Figure 6. Translational pathway from formulation design to clinical application.

4.CONCLUSION

Drug discovery is a multidisciplinary pathway extending from target or lead identification through optimization, preclinical testing, clinical research, regulatory evaluation and post-market monitoring. Targeted drug delivery seeks to improve the spatial and temporal exposure of therapeutic agents and may use passive, active, stimulus-responsive or combined approaches. Nanocarriers such as liposomes, polymeric nanoparticles, lipid nanoparticles, micelles and dendrimers provide adaptable platforms for modifying drug distribution and release.

The evidence also demonstrates that targeted delivery is not automatically synonymous with selective clinical therapy. Biological heterogeneity, target accessibility, biodistribution, immune clearance, manufacturing complexity, safety and translational differences between experimental models and humans remain important considerations. Future progress will depend on rigorous characterization, reproducible manufacturing, appropriate biological models and clinically meaningful evaluation. For Rasa Shastra and Bhaishajya Kalpana, contemporary drug-delivery science may offer useful analytical and pharmaceutical tools, but proposed mechanistic links should be established through reproducible experimental evidence.

5. REFERENCES (VANCOUVER STYLE

1. U.S. Food and Drug Administration. The drug development process [Internet]. Silver Spring (MD): FDA; 2018 [cited 2026 Oct 3]. Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drugdevelopment-process

2. Jain KK. An overview of drug delivery systems. Methods Mol Biol. 2020;2059:1-54. doi:10.1007/978-1-4939-97985_1.

3. Attia MAB, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185-1198.

doi:10.1111/jphp.13098.

4. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. doi:10.1038/s41573-020-0090-8.

5. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48. doi:10.1016/j.addr.2012.09.037.

6. van der Meel R, Lammers T, Hennink WE, Storm G. Cancer nanomedicines: oversold or underappreciated? Expert Opin Drug Deliv. 2017;14(1):1-4. doi:10.1080/17425247.2016.1213243.

7. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25-38. doi:10.1016/j.addr.2016.04.025.

8. U.S. Food and Drug Administration. Step 4: FDA drug review [Internet]. Silver Spring (MD): FDA; 2018 [cited 2026 Oct 3]. Available from: https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review

9. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37. doi:10.1038/nrc.2016.108.

10. Rosenblum D, Joshi N, Tao W, Karp JM, Farokhzad OC. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410. doi:10.1038/s41467-018-03705-y.

11. Patel NR, Pattni BS, Abouzeid AH, Torchilin VP. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev. 2013;65(13-14):1748-1762. doi:10.1016/j.addr.2013.05.001.

12. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760. doi:10.1038/nnano.2007.387.

13. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine:
the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1):1-14.
doi:10.2217/nnm.12.132.

14. Bi Y, Hao F, Yan G, Teng L, Lee RJ, Xie J. Actively targeted nanoparticles for drug delivery to tumor. Curr Med Chem. 2016;23(31):3099-3115. doi:10.2174/0929867323666160619191853.

15. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug co-delivery. Front Pharmacol. 2015;6:286. doi:10.3389/fphar.2015.00286.